PT Phapros, Tbk acquired an additional 35.22% stake in PT. Lucas Djaja.
November 29, 2018
Share
PT Phapros, Tbk (IDX:PEHA) acquired an additional 35.22% stake in PT Lucas Djaja Group on November 30, 2018. Post completion, PT Phapros, Tbk holds 90.22% stake in PT Lucas Djaja Group.
PT Phapros, Tbk (IDX:PEHA) completed the acquisition of an additional 35.22% stake in PT Lucas Djaja Group on November 30, 2018. The value of 90.22% stake is approximately IDR 320 million.
PT Phapros Tbk is an Indonesia-based pharmaceutical company. The Company's business pillars consist of branded/ethical prescription medicines: hospitals and pharmacies in addition to other healthcare institutions; over-the-counter drugs: pharmacies, retail; generic prescription drugs: government institutions and hospitals; toll-in manufacturing, and medical device. It offers medicines for cardiovascular and hematopoietic, gastrointestinal and hepatobiliary, hormone Genito, urinary endocrine and metabolic, vitamins and minerals nutrition, dermatology, local anesthesia, immune & allergy, and others. The Company's medical devices include ACS MB system, ACS FB and FB PS, Primary Hip Stem, INASHUNT Semilunar Flushing, BoneFill Ortho and NPC-STRIP G. Its branded drugs include Colkatriol 0.25 mcg 30 Cap, Diafac XR, Diafac 500 mg 10 tablets, Spirolactone 25 & 1, Dextamine Syrup 60 ml, Diapros Tablet, Proinfarction, anemone, Pladel, and others. The Company also operates calibration laboratory.
PT PHAPROS TBK 
